IM Cannabis Corp. (IMCC)
USD 2.11
(-8.26%)
USD 2.11
(-8.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.79 Million CAD | 25.81% |
| 2022 | -16.75 Million CAD | -16.33% |
| 2021 | -10.63 Million USD | -51.12% |
| 2020 | -7.03 Million CAD | -194.6% |
| 2019 | -6.02 Million CAD | -173.21% |
| 2018 | 3.26 Million CAD | 2711.03% |
| 2017 | 1.07 Million CAD | -719.48% |
| 2016 | -15.25 Thousand CAD | 65.31% |
| 2015 | -43.95 Thousand CAD | 80.13% |
| 2014 | -221.17 Thousand CAD | -18.48% |
| 2013 | -186.66 Thousand CAD | -101.97% |
| 2012 | 9.45 Million CAD | 1963.06% |
| 2011 | -507.73 Thousand CAD | 22.92% |
| 2010 | -658.71 Thousand CAD | 49.62% |
| 2009 | -1.3 Million CAD | 14.79% |
| 2008 | -1.53 Million CAD | -329.96% |
| 2007 | -356.9 Thousand CAD | -127.43% |
| 2006 | -156.92 Thousand CAD | -298.62% |
| 2005 | 79 Thousand CAD | 118.77% |
| 2004 | -420.89 Thousand CAD | -338.4% |
| 2003 | 176.55 Thousand CAD | 117.25% |
| 2002 | 34.58 Thousand CAD | -3059.44% |
| 2001 | 34.58 Thousand CAD | -68.81% |
| 2000 | 110.89 Thousand CAD | 10.89% |
| 1999 | 100 Thousand CAD | 0.0% |
| 1998 | 100 Thousand CAD | -83.33% |
| 1997 | 600 Thousand CAD | -45.45% |
| 1996 | 1 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.41 Million CAD | 51.25% |
| 2024 Q1 | -4.91 Million CAD | -149.64% |
| 2023 Q3 | -5.71 Million CAD | -792.97% |
| 2023 Q2 | -640 Thousand CAD | -133.42% |
| 2023 FY | - CAD | 25.81% |
| 2023 Q4 | -4.43 Million CAD | 22.41% |
| 2023 Q1 | 1.91 Million CAD | 127.65% |
| 2022 Q2 | -7.81 Million CAD | -154.2% |
| 2022 Q1 | -3.07 Million CAD | 66.55% |
| 2022 FY | - CAD | -16.33% |
| 2022 Q4 | -6.92 Million CAD | -86.28% |
| 2022 Q3 | -3.71 Million CAD | 52.42% |
| 2021 Q1 | 5.9 Million CAD | 194.12% |
| 2021 Q4 | -9.19 Million USD | -126.35% |
| 2021 Q2 | -3.25 Million CAD | -155.05% |
| 2021 FY | - USD | -51.12% |
| 2021 Q3 | -4.06 Million CAD | -24.88% |
| 2020 Q1 | 1.98 Million CAD | 180.95% |
| 2020 FY | - CAD | -194.6% |
| 2020 Q2 | -2.32 Million CAD | -216.94% |
| 2020 Q4 | -6.27 Million CAD | -926.75% |
| 2020 Q3 | 759 Thousand CAD | 132.72% |
| 2019 Q1 | -10.62 Thousand CAD | 43.71% |
| 2019 Q4 | -2.45 Million CAD | -6.06% |
| 2019 Q3 | -2.31 Million CAD | -547530.33% |
| 2019 FY | - CAD | -173.21% |
| 2019 Q2 | -422.00 CAD | 96.03% |
| 2018 Q2 | -60.94 Thousand CAD | 34.43% |
| 2018 Q4 | -18.88 Thousand CAD | -101.09% |
| 2018 Q1 | -92.94 Thousand CAD | -359.7% |
| 2018 FY | - CAD | 2711.03% |
| 2018 Q3 | 1.73 Million CAD | 2951.94% |
| 2017 Q3 | -10.38 Thousand CAD | -628.42% |
| 2017 FY | - CAD | -719.48% |
| 2017 Q1 | -15.25 Thousand CAD | 0.0% |
| 2017 Q2 | -1425.00 CAD | 90.66% |
| 2017 Q4 | -20.21 Thousand CAD | -94.79% |
| 2016 FY | - CAD | 65.31% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2015 FY | - CAD | 80.13% |
| 2014 Q1 | -31.05 Thousand CAD | 55.05% |
| 2014 Q3 | -76.01 Thousand CAD | -127.73% |
| 2014 Q4 | 15.59 Thousand CAD | 120.52% |
| 2014 Q2 | -33.37 Thousand CAD | -7.48% |
| 2014 FY | - CAD | -18.48% |
| 2013 Q4 | -69.09 Thousand CAD | -116.71% |
| 2013 Q2 | -54.64 Thousand CAD | -100.56% |
| 2013 Q1 | 9.67 Million CAD | 13266.35% |
| 2013 Q3 | -31.88 Thousand CAD | 41.65% |
| 2013 FY | - CAD | -101.97% |
| 2012 Q4 | -73.46 Thousand CAD | -1.64% |
| 2012 Q1 | -116.07 Thousand CAD | -48.19% |
| 2012 Q2 | -68.04 Thousand CAD | 41.38% |
| 2012 Q3 | -72.28 Thousand CAD | -6.23% |
| 2012 FY | - CAD | 1963.06% |
| 2011 Q4 | -78.33 Thousand CAD | 38.51% |
| 2011 Q3 | -127.39 Thousand CAD | 31.48% |
| 2011 Q2 | -185.92 Thousand CAD | 15.77% |
| 2011 Q1 | -220.75 Thousand CAD | -115.87% |
| 2011 FY | - CAD | 22.92% |
| 2010 Q4 | -102.26 Thousand CAD | 55.17% |
| 2010 Q1 | -298.7 Thousand CAD | 56.45% |
| 2010 Q2 | -107.59 Thousand CAD | 63.98% |
| 2010 Q3 | -228.1 Thousand CAD | -112.01% |
| 2010 FY | - CAD | 49.62% |
| 2009 Q4 | -685.84 Thousand CAD | -328.41% |
| 2009 Q2 | -162.92 Thousand CAD | 29.28% |
| 2009 Q1 | -230.39 Thousand CAD | 6.84% |
| 2009 FY | - CAD | 14.79% |
| 2009 Q3 | -160.09 Thousand CAD | 1.74% |
| 2008 Q4 | -247.29 Thousand CAD | -108.49% |
| 2008 Q3 | -118.61 Thousand CAD | 86.94% |
| 2008 Q2 | -908.2 Thousand CAD | -785.17% |
| 2008 FY | - CAD | -329.96% |
| 2008 Q1 | -102.6 Thousand CAD | 16.13% |
| 2007 Q2 | -60.36 Thousand CAD | 48.52% |
| 2007 FY | - CAD | -127.43% |
| 2007 Q1 | -117.25 Thousand CAD | -115.98% |
| 2007 Q4 | -122.33 Thousand CAD | -57.31% |
| 2007 Q3 | -77.76 Thousand CAD | -28.84% |
| 2006 Q4 | -54.28 Thousand CAD | 53.64% |
| 2006 Q3 | -117.1 Thousand CAD | -94.54% |
| 2006 FY | - CAD | -298.62% |
| 2006 Q1 | -105.29 Thousand CAD | -77.43% |
| 2006 Q2 | -60.19 Thousand CAD | 42.83% |
| 2005 FY | - CAD | 118.77% |
| 2005 Q4 | -59.34 Thousand CAD | 40.53% |
| 2005 Q3 | -99.78 Thousand CAD | -19.46% |
| 2005 Q2 | -83.53 Thousand CAD | 57.12% |
| 2005 Q1 | -194.8 Thousand CAD | -244.8% |
| 2004 Q1 | -195.23 Thousand CAD | -136.71% |
| 2004 FY | - CAD | -338.4% |
| 2004 Q2 | -82.65 Thousand CAD | 57.66% |
| 2004 Q3 | -86.93 Thousand CAD | -5.18% |
| 2004 Q4 | -56.49 Thousand CAD | 35.01% |
| 2003 Q2 | -53.6 Thousand CAD | 79.71% |
| 2003 Q3 | -114.65 Thousand CAD | -127.24% |
| 2003 Q1 | -248.73 Thousand CAD | -308.24% |
| 2003 FY | - CAD | 117.25% |
| 2003 Q4 | -46.97 Thousand CAD | 563.8% |
| 2002 FY | - CAD | -3059.44% |
| 2002 Q3 | -659.38 Thousand CAD | -1111.77% |
| 2002 Q1 | -38.54 Thousand CAD | -507.59% |
| 2002 Q4 | -60.92 Thousand CAD | 90.76% |
| 2002 Q2 | -54.41 Thousand CAD | -41.17% |
| 2001 Q4 | 9457.00 CAD | 29.55% |
| 2001 Q2 | 17.82 Thousand CAD | 172.53% |
| 2001 FY | - CAD | -68.81% |
| 2001 Q1 | 6541.00 CAD | -62.23% |
| 2001 Q3 | 7300.00 CAD | -59.05% |
| 2000 Q1 | -500 Thousand CAD | -600.0% |
| 2000 Q4 | 17.31 Thousand CAD | 1731800.0% |
| 2000 Q3 | 1.00 CAD | -100.0% |
| 2000 Q2 | 100 Thousand CAD | 120.0% |
| 2000 FY | - CAD | 10.89% |
| 1999 Q3 | 100 Thousand CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| 1999 Q4 | 100 Thousand CAD | 0.0% |
| 1999 Q2 | 100 Thousand CAD | 200.0% |
| 1999 Q1 | -100 Thousand CAD | -200.0% |
| 1998 Q3 | 100 Thousand CAD | 0.0% |
| 1998 FY | - CAD | -83.33% |
| 1998 Q4 | 100 Thousand CAD | 0.0% |
| 1998 Q1 | -100 Thousand CAD | -133.33% |
| 1998 Q2 | 100 Thousand CAD | 200.0% |
| 1997 Q3 | 200 Thousand CAD | 100.0% |
| 1997 Q2 | 100 Thousand CAD | 0.0% |
| 1997 FY | - CAD | -45.45% |
| 1997 Q4 | 300 Thousand CAD | 50.0% |
| 1996 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -292.488% |
| Harrow Health, Inc. | 9.72 Million USD | 128.695% |
| Dynavax Technologies Corporation | 9.66 Million USD | 128.864% |
| Biofrontera Inc. | -18.45 Million USD | 84.881% |
| DURECT Corporation | -24.68 Million USD | 88.697% |
| Cronos Group Inc. | -72.14 Million USD | 96.133% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.698% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 92.268% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 110.622% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 28.869% |
| Radius Health, Inc. | 38.31 Million USD | 107.283% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 13.221% |
| ProPhase Labs, Inc. | -14.82 Million USD | 81.183% |
| Phibro Animal Health Corporation | 84.6 Million USD | 103.298% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -18.672% |
| Procaps Group S.A. | 104.02 Million USD | 102.682% |
| Alvotech | -484.86 Million USD | 99.425% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 66.79% |
| Rockwell Medical, Inc. | -4.69 Million USD | 40.562% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 27.048% |
| Alpha Teknova, Inc. | -25.53 Million USD | 89.076% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 98.244% |
| SCYNEXIS, Inc. | 73.47 Million USD | 103.797% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -175.692% |
| Theratechnologies Inc. | -10.31 Million USD | 72.946% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 102.552% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 38.343% |
| Safety Shot Inc | -12.18 Million USD | 77.103% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 102.839% |
| SIGA Technologies, Inc. | 84.15 Million USD | 103.315% |
| Tilray Brands, Inc. | -72.84 Million USD | 96.17% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 443.596% |
| Viatris Inc. | 3.51 Billion USD | 100.079% |
| PetIQ, Inc. | 81.48 Million USD | 103.424% |
| OptiNose, Inc. | -15.55 Million USD | 82.061% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 100.671% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 27.048% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 107.743% |
| Alimera Sciences, Inc. | 7.27 Million USD | 138.345% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 100.905% |
| Silver Spike Investment Corp. | 7.34 Million USD | 138.01% |
| Assertio Holdings, Inc. | -222.44 Million USD | 98.746% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 30.087% |
| Cosmos Health Inc. | -17.06 Million USD | 83.648% |
| Journey Medical Corporation | 1.92 Million USD | 245.237% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 33.759% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 83.397% |
| Embecta Corp. | 245.4 Million USD | 101.137% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 22.878% |
| Procaps Group, S.A. | 104.02 Million USD | 102.682% |
| PainReform Ltd. | -9.56 Million USD | 70.843% |
| Incannex Healthcare Limited | -18.5 Million USD | 84.922% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 86.071% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 98.129% |
| Shineco, Inc. | -26.55 Million USD | 89.493% |
| Talphera, Inc. | -9.84 Million USD | 71.652% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 101.713% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 336.041% |
| Alvotech | -484.86 Million USD | 99.425% |
| Hempacco Co., Inc. | -12.77 Million USD | 78.158% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 103.6% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.568% |
| Bright Green Corporation | - USD | Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 98.141% |
| Kamada Ltd. | 21.53 Million USD | 112.956% |
| Indivior PLC | 66 Million USD | 104.227% |
| Evoke Pharma, Inc. | -7.29 Million USD | 61.74% |
| Flora Growth Corp. | -45.87 Million USD | 93.918% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 86.071% |
| Evolus, Inc. | -41.81 Million USD | 93.327% |
| HUTCHMED (China) Limited | 25.52 Million USD | 110.929% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 101.155% |
| Akanda Corp. | -27.73 Million USD | 89.941% |